Journal of Clinical Nutrition and Metabolism

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Efficacy of VIQUA® in Alleviating PMS Symptoms

Introduction: Pre-Menstrual Syndrome (PMS) is considered as a disorder with neuro-hormonal and gynecological dimensions. As a high prevalent condition that affects the quality of life for women, there is an increasing demand in using nutritional supplements to alleviate the symptoms of PMS. Pomegranate is a fruit containing different bioactive molecules that are previously shown to have anti-inflammatory and anti-depression properties suggesting its possible efficacy in physiological as well as psychological symptoms seen associated with PMS. This study attempted to evaluate the efficacy and safety profiles of VIQUA®, a pomegranate based polyphenol complex in subjects with PMS.

Materials and methods: This was a single center, prospective, randomized, double blind, two arm, parallel, placebo controlled; clinical study adhered to the good clinical practice guidelines and was approved by the ethical review board. Forty female adult subjects aged between 25-35 years participated in the study and all subjects completed the study without any adverse events. PMS symptoms were assessed using Premenstrual Symptoms Screening Tools Questionnaire (PSST) for 3 consecutive menstrual cycles. Plasma Brain Derived Neurotrophic Factor (BDNF) levels and serum 14-Dihydro-15- Keto Prostaglandin F2-Alpha (PGFM) were evaluated to understand the impact of test product supplementation in neurotransmitter and prostaglandin levels.

Results: At the end of 3rd menstrual cycle, mean PSST score in VIQUA® group showed a statistically significant reduction compared to baseline (P value>0.0001). In the subgroup analysis of PSST score, VIQUA® group showed significant reduction in physical symptoms score, psychological symptoms score and interfering symptoms scores. Compared to baseline, VIQUA® group showed a significant improvement in BDNF levels (P value>0.05) and significant reduction in 14- Dihydro-15-Keto Prostaglandin F2-Alpha (PGFM) levels (P value>0.05). It was also noted that VIQUA® group had a considerable increase in the fecal Short Chain Fatty Acids (SCFA) levels.

Conclusion: Considering the significant improvement in different aspects of PMS including inflammation, pain and psychological and psycho-somatic factors, VIQUA® shows great prospects as an effective supplement in treating PMS symptoms.

Special Features

Full Text

View

Track Your Manuscript

Media Partners

GET THE APP